SG11201402152YA - Polymer protein microparticles - Google Patents

Polymer protein microparticles

Info

Publication number
SG11201402152YA
SG11201402152YA SG11201402152YA SG11201402152YA SG11201402152YA SG 11201402152Y A SG11201402152Y A SG 11201402152YA SG 11201402152Y A SG11201402152Y A SG 11201402152YA SG 11201402152Y A SG11201402152Y A SG 11201402152YA SG 11201402152Y A SG11201402152Y A SG 11201402152YA
Authority
SG
Singapore
Prior art keywords
polymer protein
protein microparticles
microparticles
polymer
protein
Prior art date
Application number
SG11201402152YA
Inventor
Hunter Chen
Scott Walsh
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47295198&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201402152Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201402152YA publication Critical patent/SG11201402152YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
SG11201402152YA 2011-11-18 2012-11-18 Polymer protein microparticles SG11201402152YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161561525P 2011-11-18 2011-11-18
PCT/US2012/065735 WO2013075068A1 (en) 2011-11-18 2012-11-18 Polymer protein microparticles

Publications (1)

Publication Number Publication Date
SG11201402152YA true SG11201402152YA (en) 2014-06-27

Family

ID=47295198

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201402152YA SG11201402152YA (en) 2011-11-18 2012-11-18 Polymer protein microparticles
SG10202103003RA SG10202103003RA (en) 2011-11-18 2012-11-18 Polymer protein microparticles

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202103003RA SG10202103003RA (en) 2011-11-18 2012-11-18 Polymer protein microparticles

Country Status (20)

Country Link
US (3) US20130129830A1 (en)
EP (4) EP3384903B1 (en)
JP (5) JP6267649B2 (en)
KR (4) KR102218223B1 (en)
CN (2) CN105688188A (en)
AU (1) AU2012340107B2 (en)
BR (1) BR112014011915B1 (en)
CA (2) CA3076725A1 (en)
DK (3) DK3574897T3 (en)
ES (3) ES2775104T5 (en)
FI (1) FI2790681T4 (en)
HU (2) HUE048597T2 (en)
IL (4) IL277958B2 (en)
MX (2) MX362286B (en)
PL (3) PL2790681T5 (en)
PT (2) PT3574897T (en)
RU (2) RU2768492C2 (en)
SG (2) SG11201402152YA (en)
WO (1) WO2013075068A1 (en)
ZA (2) ZA201403379B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP4108671A1 (en) 2010-10-01 2022-12-28 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN103974724B (en) 2011-10-03 2019-08-30 现代泰克斯公司 Nucleosides, nucleotide and nucleic acid of modification and application thereof
JP6267649B2 (en) 2011-11-18 2018-01-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Polymer protein fine particles
CA2859387A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP6144355B2 (en) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Chemically modified mRNA
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (en) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. POLYNUCLEOTES ENCODING THE RECEPTOR OF LOW DENSITY LIPOPROTEINS
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016011226A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
SG11201803197UA (en) * 2015-12-16 2018-05-30 Regeneron Pharma Compositions and methods of manufacturing protein microparticles
HRP20220525T1 (en) 2015-12-23 2022-05-27 Modernatx, Inc. Methods of using ox40 ligand encoding polynucleotides
RU2744860C2 (en) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Antibodies and their conjugates
MA43587A (en) 2016-01-10 2018-11-14 Modernatx Inc THERAPEUTIC RNA CODING FOR ANTI-CTLA-4 ANTIBODIES
WO2018213731A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
EP3459529A1 (en) 2017-09-20 2019-03-27 Tillotts Pharma Ag Preparation of sustained release solid dosage forms comprising antibodies by spray drying
US20220098279A1 (en) * 2019-01-30 2022-03-31 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
MX2022006236A (en) 2019-11-25 2022-06-22 Regeneron Pharma Sustained release formulations using non-aqueous emulsions.
CN115887760A (en) * 2022-11-21 2023-04-04 娜罗曼苏(杭州)医疗生物科技有限公司 Preparation process of L-polylactic acid for injection

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210529A (en) 1974-12-26 1980-07-01 Midwest Research Institute Blood compatible polymers and applications thereof
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4764364A (en) 1986-02-25 1988-08-16 S R I International Method of preparing bioerodible polymers having pH sensitivity in the acid range and resulting product
US5104221A (en) 1989-03-03 1992-04-14 Coulter Electronics Of New England, Inc. Particle size analysis utilizing polarization intensity differential scattering
DE10399023I2 (en) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-binding proteins
GB9107628D0 (en) * 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
US6063910A (en) 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
EP0661989B1 (en) 1992-09-21 1997-08-06 PHARMACIA & UPJOHN COMPANY Sustained-release protein formulations
GB9415810D0 (en) * 1994-08-04 1994-09-28 Jerrow Mohammad A Z Composition
JP3971797B2 (en) 1994-09-23 2007-09-05 アレクション・ファーマシューティカルズ・インク Method for treating inflammatory joint diseases
US6004549A (en) 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5968543A (en) 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
EP0913177A1 (en) 1997-11-03 1999-05-06 Roche Diagnostics GmbH Process for producing dry, amorphous products comprising biological active materials by means of convection drying technique, especially spray drying
ES2217738T3 (en) 1998-01-29 2004-11-01 Poly-Med Inc. ABSORBABLE MICROPARTICLES.
US6284282B1 (en) 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6223455B1 (en) * 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
AU1226901A (en) 1999-10-22 2001-05-08 Amgen, Inc. Biodegradable microparticles with novel erythropoietin stimulating protein
FR2809309B1 (en) * 2000-05-23 2004-06-11 Mainelab EXTENDED RELEASE MICROSPHERES FOR INJECTION DELIVERY
JP2004515467A (en) 2000-08-07 2004-05-27 ネクター セラピューティックス Inhalable, spray-dried, 4-helix bundle protein powder with minimal aggregates
CA2451185A1 (en) 2001-06-21 2003-01-03 Altus Biologics, Inc. Spherical protein particles and methods of making and using them
WO2003006052A1 (en) * 2001-07-09 2003-01-23 Yamanouchi Pharmaceutical Co., Ltd. Sustained-release compositions for injection and process for producing the same
SG106672A1 (en) 2002-03-08 2004-10-29 Asml Netherlands Bv Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method
WO2003092665A2 (en) * 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
EP2460530A3 (en) 2002-12-31 2012-08-29 Althea Technologies, Inc. Human growth hormone crystals and methods for preparing them
US20040208928A1 (en) * 2003-04-15 2004-10-21 Animal Technology Institute Taiwan Method for preparing an orally administrable formulation for controlled release
AR047552A1 (en) 2003-06-26 2006-01-25 Control Delivery Sys Inc SUPPLY SYSTEMS OF BIODEGRADABLE SUSTAINED RELEASE PHARMACOS
DE10339197A1 (en) 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried amorphous powder with low residual moisture and good storage stability
KR20060104989A (en) * 2003-10-01 2006-10-09 데비오 레쉑쉐 빠르마슈띠끄 에스.아 Device and method for making particles
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7572893B2 (en) 2004-08-17 2009-08-11 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
US7655758B2 (en) 2004-08-17 2010-02-02 Regeneron Pharmaceuticals, Inc. Stable liquid IL-1 antagonist formulations
CN101014617B (en) 2004-08-17 2011-03-30 瑞泽恩制药公司 Il-1 antagonist formulations
US20060110429A1 (en) 2004-11-24 2006-05-25 Therakine Corporation Implant for intraocular drug delivery
EP1830810A4 (en) 2004-12-30 2011-02-02 Dobeel Co Ltd Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same
US20060217311A1 (en) 2005-03-25 2006-09-28 Daniel Dix VEGF antagonist formulations
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
PL1959925T3 (en) † 2005-12-02 2017-05-31 (Osi) Eyetech, Inc. Controlled release microparticles
KR100722607B1 (en) 2006-05-11 2007-05-28 주식회사 펩트론 A process of preparing microspheres for sustained release having improved dispersibility and syringeability
LT2944306T (en) 2006-06-16 2021-02-25 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
DE102006030166A1 (en) * 2006-06-29 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg temper
DE102006030164A1 (en) 2006-06-29 2008-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative powders
EP1958622A1 (en) 2006-11-07 2008-08-20 Royal College of Surgeons in Ireland Method of producing microcapsules
WO2008109886A1 (en) 2007-03-08 2008-09-12 The Regents Of The University Of California Topographically engineered structures and methods for using the same in regenerative medicine applications
ES2558544T3 (en) 2007-03-16 2016-02-05 The Regents Of The University Of California Medical implants coated on the nanostructure surface and their methods of use
KR100805208B1 (en) * 2007-03-27 2008-02-21 주식회사 펩트론 Composition and microsphere for controlled-release of exendin and method of preparing the same
JP2010532749A (en) * 2007-06-07 2010-10-14 サーモディクス ファーマシューティカルズ， インコーポレイテッド Long acting dosage form with reduced mass
AU2008340785B8 (en) 2007-12-21 2014-09-18 Merck Patent Gmbh Solid lipid microcapsules containing growth hormone in the inner solid core
JP6078217B2 (en) 2008-01-15 2017-02-08 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー Powdered protein composition and method for producing the same
CA2757037C (en) 2009-01-29 2019-08-06 Forsight Vision4, Inc. Posterior segment drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
PT3130396T (en) * 2009-03-27 2021-05-12 Bend Res Inc Spray-drying process
CN101559041B (en) 2009-05-19 2014-01-15 中国科学院过程工程研究所 Polypeptide medicament sustained release microsphere or microcapsule preparation with uniform grain size and preparation method thereof
MX342623B (en) 2009-06-26 2016-10-06 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format.
US8417452B2 (en) 2009-08-19 2013-04-09 General Motors Llc System for providing information to an operator of a vehicle
US20110104151A1 (en) * 2009-10-01 2011-05-05 Heather Nettles Microparticle compositions and methods for treating age-related macular degeneration
JO3417B1 (en) 2010-01-08 2019-10-20 Regeneron Pharma Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
JOP20190250A1 (en) 2010-07-14 2017-06-16 Regeneron Pharma Stabilized formulations containing anti-ngf antibodies
RS62540B1 (en) 2010-08-05 2021-12-31 Forsight Vision4 Inc Apparatus to treat an eye
RS61601B1 (en) 2010-08-05 2021-04-29 Forsight Vision4 Inc Injector apparatus for drug delivery
EP2624865B1 (en) 2010-10-06 2018-08-01 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
CA2833144C (en) 2011-04-14 2020-09-29 The Regents Of The University Of California Multilayer thin film drug delivery device and methods of making and using the same
AR087305A1 (en) 2011-07-28 2014-03-12 Regeneron Pharma STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES, PREPARATION METHOD AND KIT
JP6267649B2 (en) 2011-11-18 2018-01-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Polymer protein fine particles
RU2711089C2 (en) 2012-05-18 2020-01-15 Дженентек, Инк. Highly concentrated compositions of monoclonal antibodies
US9878137B2 (en) 2012-05-30 2018-01-30 The Regents Of The University Of California Bioactive agent delivery devices and methods of making and using the same
WO2014039964A2 (en) 2012-09-10 2014-03-13 The Regents Of The University Of California Compounds and methods for modulating vascular injury
WO2014147131A1 (en) 2013-03-19 2014-09-25 Biotech Tools S.A. Allergen preparation
EP3929218A1 (en) 2014-07-14 2021-12-29 Amgen, Inc Crystalline antibody formulations
EA036623B1 (en) 2015-10-16 2020-12-01 Ридженерон Фармасьютикалз, Инк. Stable protein compositions
BR112018008608B1 (en) 2015-11-05 2022-05-17 Basf Se Use of formula i compounds, formula i compounds, compounds, agrochemical composition and method to combat phytopathogenic harmful fungi
US20200289514A1 (en) 2015-11-13 2020-09-17 Novartis Ag Novel Pyrazolo Pyrimidine Derivatives
TW201731867A (en) 2015-12-02 2017-09-16 賽諾菲公司 FGF21 variants
WO2017100159A2 (en) 2015-12-07 2017-06-15 Celanese International Corporation Cellulose acetate film forming compositions
EP3390357B1 (en) 2015-12-15 2021-11-10 Merck Sharp & Dohme Corp. Biaryl monobactam compounds for the treatment of bacterial infections
SG11201803197UA (en) 2015-12-16 2018-05-30 Regeneron Pharma Compositions and methods of manufacturing protein microparticles

Also Published As

Publication number Publication date
ES2810003T3 (en) 2021-03-08
EP2790681B1 (en) 2020-01-22
US20220249387A1 (en) 2022-08-11
JP2020169195A (en) 2020-10-15
IL232328B (en) 2018-11-29
EP2790681A1 (en) 2014-10-22
US11291636B2 (en) 2022-04-05
ZA201800078B (en) 2020-05-27
PL2790681T3 (en) 2020-07-27
US11951216B2 (en) 2024-04-09
DK2790681T3 (en) 2020-04-14
RU2018101248A (en) 2019-02-21
ES2775104T3 (en) 2020-07-23
IL262651B (en) 2020-11-30
IL277958B2 (en) 2023-11-01
MX2019000382A (en) 2023-01-05
CA2855749C (en) 2020-05-26
ZA201403379B (en) 2020-12-23
RU2014124682A (en) 2015-12-27
KR20220063293A (en) 2022-05-17
PL3384903T3 (en) 2020-10-19
DK2790681T4 (en) 2023-05-01
JP6549653B2 (en) 2019-07-24
HUE048597T2 (en) 2020-07-28
KR20140096327A (en) 2014-08-05
SG10202103003RA (en) 2021-05-28
IL262651A (en) 2018-12-31
BR112014011915B1 (en) 2022-08-30
DK3574897T3 (en) 2022-04-04
CA3076725A1 (en) 2013-05-23
WO2013075068A1 (en) 2013-05-23
US20170181978A1 (en) 2017-06-29
PT3574897T (en) 2022-04-06
IL232328A0 (en) 2014-06-30
JP2014533698A (en) 2014-12-15
EP3384903B1 (en) 2020-05-27
JP6267649B2 (en) 2018-01-24
CN103957898B (en) 2016-02-24
PT3384903T (en) 2020-06-25
RU2018101248A3 (en) 2021-02-18
CN103957898A (en) 2014-07-30
EP3574897A1 (en) 2019-12-04
RU2768492C2 (en) 2022-03-24
CN105688188A (en) 2016-06-22
RU2642664C2 (en) 2018-01-25
JP2023052564A (en) 2023-04-11
EP4026543A1 (en) 2022-07-13
ES2775104T5 (en) 2023-06-08
IL277958A (en) 2020-11-30
MX362286B (en) 2019-01-10
KR20210021112A (en) 2021-02-24
JP2019135255A (en) 2019-08-15
PL2790681T5 (en) 2024-02-05
KR20200018712A (en) 2020-02-19
EP3384903A1 (en) 2018-10-10
KR102218223B1 (en) 2021-02-22
ES2909777T3 (en) 2022-05-10
EP2790681B9 (en) 2023-07-26
MX2014005997A (en) 2014-08-27
JP2018008990A (en) 2018-01-18
JP6727372B2 (en) 2020-07-22
HUE051644T2 (en) 2021-03-01
EP2790681B2 (en) 2023-02-22
FI2790681T4 (en) 2023-05-04
BR112014011915A2 (en) 2017-05-16
PL3574897T3 (en) 2022-05-09
IL277958B1 (en) 2023-07-01
JP7217247B2 (en) 2023-02-02
DK3384903T3 (en) 2020-07-20
IL303832A (en) 2023-08-01
US20130129830A1 (en) 2013-05-23
CA2855749A1 (en) 2013-05-23
AU2012340107B2 (en) 2017-06-15
AU2012340107A1 (en) 2014-06-05
EP3574897B1 (en) 2022-01-05
KR102133352B1 (en) 2020-07-14

Similar Documents

Publication Publication Date Title
IL277958A (en) Polymer protein microparticles
HK1198356A1 (en) Macromolecules
EP2754747A4 (en) Molded inorganic-fiber object
ZA201309001B (en) Polymer particles
GB2501047B (en) Polymer
GB201221246D0 (en) Polymer blends
GB201111183D0 (en) Peptide
GB201115910D0 (en) Peptides
GB2499491B (en) Compatibilised polymer blends
EP2733361A4 (en) Turbocompressor
GB201105482D0 (en) Polymers
PL2794110T3 (en) Granulator
EP2707420A4 (en) Polymers and plastics derived from animal proteins
EP2728198A4 (en) Turbocompressor
GB201107468D0 (en) Protein expression systems
EP2773330A4 (en) Processes for producing protein microparticles
GB201213672D0 (en) Protein
EP2714717A4 (en) Phoenixin peptides
EP2733360A4 (en) Turbocompressor
GB2487794B (en) Microparticles
AU2012905215A0 (en) Microparticles
GB201215901D0 (en) Protein modification
GB201103169D0 (en) Protein expression
HUP1100282A2 (en) Protein factor
GB201113089D0 (en) Protein hydrolysates